New combo therapy aims to tame returning head and neck cancer
NCT ID NCT07156227
First seen Nov 01, 2025 · Last updated May 10, 2026 · Updated 32 times
Summary
This early-stage trial tests a drug called camonsertib combined with precise, high-dose radiation for people whose head and neck cancer has come back or cannot be removed by surgery. The study will include about 39 adults and aims to find the safest dose and see if the combination can control the disease. The drug works by blocking a protein that cancer cells need to grow, while the radiation targets tumors directly.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLINICAL STAGE III HPV-MEDIATED (P16-POSITIVE) OROPHARYNGEAL CARCINOMA AJCC V8 are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.